Sarepta Therapeutics Inc banner

Sarepta Therapeutics Inc
XMUN:AB3A

Watchlist Manager
Sarepta Therapeutics Inc Logo
Sarepta Therapeutics Inc
XMUN:AB3A
Watchlist
Price: 18.24 EUR 3.58% Market Closed
Market Cap: €1.1B

Wall St Price Targets

AB3A Price Targets Summary
Sarepta Therapeutics Inc

Wall Street analysts forecast AB3A stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AB3A is 18.71 EUR with a low forecast of 4.18 EUR and a high forecast of 33.02 EUR.

Lowest Forecast
Price Target
4.18 EUR
77% Downside
Average Forecast
Price Target
18.71 EUR
3% Upside
Highest Forecast
Price Target
33.02 EUR
81% Upside
Sarepta Therapeutics Inc Competitors:
Price Targets
CENT
Central Garden & Pet Co
38% Upside
1981
Cathay Media and Education Group Inc
30% Upside
OFIX
Orthofix Medical Inc
47% Upside

Revenue
Forecast

32% / Year
Past Growth
-3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
32% / Year
Past Growth
-3% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 32%. The projected CAGR for the next 8 years is -3%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is AB3A's stock price target?
Price Target
18.71 EUR

According to Wall Street analysts, the average 1-year price target for AB3A is 18.71 EUR with a low forecast of 4.18 EUR and a high forecast of 33.02 EUR.

What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-3%

Over the last 14 years, the compound annual growth rate for Revenue has been 32%. The projected CAGR for the next 8 years is -3%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett